Logo image of 56S1.DE

SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock

220.9 EUR
-1.9 (-0.85%)
Last: 1/8/2026, 7:00:00 PM

56S1.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap21.50B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Shares97.33M
Float27.74M
52 Week High227.9
52 Week Low150.9
Yearly Dividend0.71
Dividend Yield0.33%
EPS(TTM)4.31
PE51.25
Fwd PE41.14
Earnings (Next)01-26 2026-01-26/amc
IPO1994-10-20
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


56S1.DE short term performance overview.The bars show the price performance of 56S1.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

56S1.DE long term performance overview.The bars show the price performance of 56S1.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30

The current stock price of 56S1.DE is 220.9 EUR. In the past month the price increased by 10.06%. In the past year, price increased by 19.99%.

SARTORIUS STEDIM BIOTECH / 56S1 Daily stock chart

56S1.DE Competitors/Peers

The largest stocks on the EU markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
DIM.PA SARTORIUS STEDIM BIOTECH 49.72 20.86B
SRT3.DE SARTORIUS AG-VORZUG 56.43 19.27B
SRT.DE SARTORIUS AG 43.51 14.86B
QIA.DE QIAGEN N.V. 20.31 8.94B
1SXP.DE SCHOTT PHARMA AG& CO KGAA 15.87 2.32B
EVT.DE EVOTEC SE N/A 2.24B
GXI.DE GERRESHEIMER AG 7.47 952.61M
FF.MI FINE FOODS & PHARMACEUTICALS 10.38 203.83M
ALECR.PA EUROFINS CEREP-REGR 24.9 178.00M
MLC.I MALIN CORP PLC N/A 34.64M

About 56S1.DE

Company Profile

56S1 logo image Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

Company Info

SARTORIUS STEDIM BIOTECH

Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex

Aubagne PACA FR

Employees: 9961

56S1 Company Website

56S1 Investor Relations

Phone: 33442845600

SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ

What does SARTORIUS STEDIM BIOTECH do?

Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.


Can you provide the latest stock price for SARTORIUS STEDIM BIOTECH?

The current stock price of 56S1.DE is 220.9 EUR. The price decreased by -0.85% in the last trading session.


Does SARTORIUS STEDIM BIOTECH pay dividends?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.33%. The yearly dividend amount is currently 0.71.


What is the ChartMill rating of SARTORIUS STEDIM BIOTECH stock?

56S1.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Would investing in SARTORIUS STEDIM BIOTECH be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 56S1.DE.


Is SARTORIUS STEDIM BIOTECH (56S1.DE) expected to grow?

The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 7.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the upcoming earnings date for SARTORIUS STEDIM BIOTECH?

SARTORIUS STEDIM BIOTECH (56S1.DE) will report earnings on 2026-01-26, after the market close.


56S1.DE Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE is one of the better performing stocks in the market, outperforming 83.05% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

56S1.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE. 56S1.DE has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

56S1.DE Financial Highlights

Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 4.31. The EPS increased by 35.11% compared to the year before.


Industry RankSector Rank
PM (TTM) 8.96%
ROA 3.35%
ROE 6.54%
Debt/Equity 0.5
Chartmill High Growth Momentum
EPS Q2Q%23.68%
Sales Q2Q%7.67%
EPS 1Y (TTM)35.11%
Revenue 1Y (TTM)7.72%

56S1.DE Forecast & Estimates

18 analysts have analysed 56S1.DE and the average price target is 240.69 EUR. This implies a price increase of 8.96% is expected in the next year compared to the current price of 220.9.

For the next year, analysts expect an EPS growth of 29.39% and a revenue growth 7.45% for 56S1.DE


Analysts
Analysts81.11
Price Target240.69 (8.96%)
EPS Next Y29.39%
Revenue Next Year7.45%

56S1.DE Ownership

Ownership
Inst Owners11.88%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A